06 Jul 2026

CRC Research Update — July 06, 2026

Creator: The CRC Digest
Published: 2026-07-06T14:43:23Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Regorafenib plus metronomic chemo shows activity in heavily pretreated mCRC
The REPROGRAM-01 phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in patients who had exhausted standard therapies including bevacizumab and anti-EGFR agents. (ESMO Gastrointestinal Oncology)
KRAS mutation linked to resistance to regorafenib plus anti-PD-1 in liver metastases
Preclinical study identifies KRAS mutation as a resistance mechanism and shows dihydroartemisinin selectively downregulates KRAS^G12D mutant protein, enhancing response to regorafenib plus immunotherapy in liver metastasis models. (Cell Death & Disease)
Caris Life Sciences launches AI-powered blood test for early cancer detection
Caris Detect uses whole genome and transcriptome sequencing with AI to detect cancer signals; in the ACHIEVE 1 study, sensitivity was 60.3% for stage I-II cancers across multiple tumor types including colorectal. (Fierce Biotech)
BREAKWATER trial presents molecular correlates in BRAF V600E metastatic CRC
Phase III data from ESMO GI 2026 examines molecular markers associated with encorafenib plus cetuximab and chemotherapy in patients with BRAF V600E-mutated metastatic colorectal cancer. (Oncodaily)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Early-onset CRC shows distinct prognostic factors compared to late-onset disease
Retrospective study of 1,148 patients (247 under age 50) used machine learning to identify age-specific prognostic factors for overall survival. (PeerJ)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Dihydroartemisinin targets KRAS^G12D to overcome immunotherapy resistance
Anti-malaria drug selectively downregulates KRAS^G12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease)
BREAKWATER explores molecular markers in BRAF V600E disease
Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

New blood test achieves 60% sensitivity for early-stage cancers
Caris Detect combines whole genome sequencing and AI; ACHIEVE 1 study showed 60.3% sensitivity for stage I-II cancers including colorectal. (Fierce Biotech)
Review examines liquid biopsy potential and limitations for CRC screening
Analysis notes promise of circulating tumor DNA and cells for detection but highlights limited sensitivity for advanced adenomas and lack of randomized trial evidence for mortality reduction. (Intestinal Research)

Research continues to advance our understanding of treatment resistance, early detection, and personalized approaches for colorectal cancer.

CRC Research Update

Subscribe to The CRC Digest